Should you buy Biogen stock now?
Yes, the technical signal for Biogen is currently Strong Buy. Biogen trades at $243.10 as of Oct 21, 2026. The technical analysis shows the following: MACD is positive (bullish trend) at 4.557 with rising momentum (signal: 3.271); RSI is at 70.6 (overbought), suggesting the price may have risen too quickly; the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $243.98 points to 0.4% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Biogen stock?
The average analyst price target for Biogen is $243.98. The current price is $243.10, which gives an upside of 0.4%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $219.58 and $268.38.
Is Biogen a dividend stock?
No, Biogen does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Biogen stock?
Biogen is rated as a stock in the risk category Conservative. the annual standard deviation is 0.0%, which classifies the stock as Conservative. In addition, an RSI of 70.6 signals overbought (elevated risk of a pullback).
Is Biogen overvalued?
Biogen is considered fairly valued – the price is close to the analyst price target. Biogen has the following valuation ratios: a P/E ratio of 41.5 (highly valued), a P/S ratio of 3.4, a P/B ratio of 1.8. The stock trades close to the analyst price target and is considered fairly valued.
Is Biogen overbought?
Yes, Biogen is overbought with an RSI of 70.6 (above 70). The technical indicators show: RSI is at 70.6 (above the 70 mark), which signals the price is overbought and may have risen too quickly. In addition, the price is 6.8% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Biogen earnings report?
Biogen reports its next earnings on October 28, 2026. The stock currently trades at $243.10. With a P/E ratio of 41.5, the market will be watching closely whether earnings meet expectations. The RSI is at 70.6, so the report can reinforce the current technical trend.
Is Biogen shorted?
Yes, Biogen is shorted with 4.5% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Biogen stock?
No, insiders are not buying Biogen shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 2 sales. On a net basis, 239,750 $ worth of shares were sold. Across the last 20 reported transactions, the split is 3 purchases and 17 sales, with a net 3,579,992 $ sold. Active sellers include Minor Lloyd, Singhal Priya, Izzar Rachid and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Biogen a good stock?
Based on our total score, Biogen is rated as a mediocre stock with a total score of 55 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 42/100, Quality: 30/100, Momentum: 95/100. Whether now is the time to buy is a separate question: the technical signal is Strong Buy. Whether Biogen is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Biogen stock?
The outlook for Biogen based on current data: the average analyst price target is $243.98 (+0.4%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on Oct 28, 2026, which can move the price; the P/E ratio is 41.5 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Biogen stock rising?
Biogen is rising right now. The technical indicators show: the price is 6.8% above the 20-day average; MACD is positive with rising momentum (bullish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Biogen go?
The average analyst price target for Biogen is $243.98, which corresponds to a potential gain of 0.4% from the current price of $243.10. The stock has traded between $138.00 and $240.99 over the last 52 weeks. The price is close to the 52-week high. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Biogen fall?
The stock has traded as low as $138.00 over the last 52 weeks — that is 43.2% below the current price of $243.10. The biggest decline (drawdown) in the same period was 42.7% from high to low. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Biogen do?
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SK... The company belongs to the Healthcare sector, more specifically the Drug Manufacturers - General industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Biogen as an investment.
Did Biogen raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Biogen. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Biogen making money or losing money?
Yes, Biogen is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 8.3% — which is moderate. The operating margin (profit before interest and taxes) is 25.1%. At a P/E ratio of 41.5, you currently pay 41.5 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Biogen go bankrupt?
The bankruptcy risk of Biogen is rated as low. Altman Z2 (a model for assessing financial distress) is 4.55 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 3 — which is weak. Debt relative to equity is 68% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Biogen have a lot of debt?
No, Biogen has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 68%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Biogen service its debt? Can service its debt, but it weighs on the company — the interest coverage ratio (how many times earnings can cover interest payments) is 2.6x, and net debt equals 2.1 years of earnings (EBITDA).